{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Systèmes CRISPR-Cas : Questions médicales les plus fréquentes",
"headline": "Systèmes CRISPR-Cas : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Systèmes CRISPR-Cas : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-26",
"dateModified": "2025-03-21",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Systèmes CRISPR-Cas"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Extinction de l'expression des gènes",
"url": "https://questionsmedicales.fr/mesh/D020868",
"about": {
"@type": "MedicalCondition",
"name": "Extinction de l'expression des gènes",
"code": {
"@type": "MedicalCode",
"code": "D020868",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.308.203.374"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Systèmes CRISPR-Cas",
"alternateName": "CRISPR-Cas Systems",
"code": {
"@type": "MedicalCode",
"code": "D064113",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Vijai Singh",
"url": "https://questionsmedicales.fr/author/Vijai%20Singh",
"affiliation": {
"@type": "Organization",
"name": "Department of Biosciences, School of Science, Indrashil University, Rajpur, Mehsana, Gujarat, India. Electronic address: vijaisingh15@gmail.com."
}
},
{
"@type": "Person",
"name": "Rodolphe Barrangou",
"url": "https://questionsmedicales.fr/author/Rodolphe%20Barrangou",
"affiliation": {
"@type": "Organization",
"name": "Genomic Sciences Graduate Program, North Carolina State University, Raleigh, NC, United States; Department of Food, Bioprocessing & Nutrition Sciences, North Carolina State University, Raleigh, NC, United States. Electronic address: rbarran@ncsu.edu."
}
},
{
"@type": "Person",
"name": "Jinzhao Long",
"url": "https://questionsmedicales.fr/author/Jinzhao%20Long",
"affiliation": {
"@type": "Organization",
"name": "Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou 450001, China."
}
},
{
"@type": "Person",
"name": "Shuaiyin Chen",
"url": "https://questionsmedicales.fr/author/Shuaiyin%20Chen",
"affiliation": {
"@type": "Organization",
"name": "Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou 450001, China."
}
},
{
"@type": "Person",
"name": "Guangcai Duan",
"url": "https://questionsmedicales.fr/author/Guangcai%20Duan",
"affiliation": {
"@type": "Organization",
"name": "Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou 450001, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Perioperative outcomes and long-term survival of cryosurgery on unresectable pancreatic cancer: a systematic review and meta-analysis.",
"datePublished": "2024-04-03",
"url": "https://questionsmedicales.fr/article/38537056",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/JS9.0000000000001407"
}
},
{
"@type": "ScholarlyArticle",
"name": "Global Prevalence and Risk of Local Recurrence Following Cryosurgery of Giant Cell Tumour of Bone: A Meta-Analysis.",
"datePublished": "2022-07-08",
"url": "https://questionsmedicales.fr/article/35884399",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/cancers14143338"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cryosurgery of eyelid actinic keratosis and the effect of adrenaline in local anesthetics - temperature mapping using IR thermography.",
"datePublished": "2024-10-09",
"url": "https://questionsmedicales.fr/article/39382124",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/01676830.2024.2403464"
}
},
{
"@type": "ScholarlyArticle",
"name": "Electrophysiology lab efficiency using cryoballoon for pulmonary vein isolation in Latin America: A sub-analysis of the Cryo Global Registry Study.",
"datePublished": "2024-09-02",
"url": "https://questionsmedicales.fr/article/39222517",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5867/medwave.2024.08.2918"
}
},
{
"@type": "ScholarlyArticle",
"name": "Safety and efficacy of lasers compared to cold knife in direct visual internal urethrotomy: a systematic review and Meta-analysis.",
"datePublished": "2024-08-05",
"url": "https://questionsmedicales.fr/article/39101963",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10103-024-04134-8"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Régulation de l'expression des gènes",
"item": "https://questionsmedicales.fr/mesh/D005786"
},
{
"@type": "ListItem",
"position": 4,
"name": "Épigenèse génétique",
"item": "https://questionsmedicales.fr/mesh/D044127"
},
{
"@type": "ListItem",
"position": 5,
"name": "Extinction de l'expression des gènes",
"item": "https://questionsmedicales.fr/mesh/D020868"
},
{
"@type": "ListItem",
"position": 6,
"name": "Systèmes CRISPR-Cas",
"item": "https://questionsmedicales.fr/mesh/D064113"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Systèmes CRISPR-Cas - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Systèmes CRISPR-Cas",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-30",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Systèmes CRISPR-Cas",
"description": "Comment identifier un système CRISPR-Cas ?\nQuels tests sont utilisés pour détecter CRISPR ?\nPeut-on détecter CRISPR dans des échantillons cliniques ?\nQuels marqueurs génétiques sont associés à CRISPR ?\nComment évaluer l'efficacité de CRISPR ?",
"url": "https://questionsmedicales.fr/mesh/D064113?mesh_terms=Cryosurgery&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Systèmes CRISPR-Cas",
"description": "Quels symptômes peuvent résulter d'une modification CRISPR ?\nY a-t-il des effets secondaires connus de CRISPR ?\nCRISPR peut-il causer des maladies ?\nQuels signes indiquent une réponse immunitaire à CRISPR ?\nComment surveiller les effets de CRISPR ?",
"url": "https://questionsmedicales.fr/mesh/D064113?mesh_terms=Cryosurgery&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Systèmes CRISPR-Cas",
"description": "CRISPR peut-il prévenir des maladies génétiques ?\nComment CRISPR peut-il être utilisé en prévention ?\nY a-t-il des risques dans l'utilisation préventive de CRISPR ?\nQuels protocoles de sécurité existent pour CRISPR ?\nCRISPR peut-il être utilisé pour prévenir des infections ?",
"url": "https://questionsmedicales.fr/mesh/D064113?mesh_terms=Cryosurgery&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Systèmes CRISPR-Cas",
"description": "CRISPR est-il utilisé pour traiter des maladies ?\nQuels types de maladies peuvent être ciblés par CRISPR ?\nComment CRISPR est-il administré en traitement ?\nQuels sont les résultats des essais cliniques avec CRISPR ?\nCRISPR peut-il être utilisé en thérapie génique ?",
"url": "https://questionsmedicales.fr/mesh/D064113?mesh_terms=Cryosurgery&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Systèmes CRISPR-Cas",
"description": "Quelles complications peuvent survenir avec CRISPR ?\nComment gérer les complications liées à CRISPR ?\nCRISPR peut-il entraîner des cancers ?\nQuels tests sont nécessaires après un traitement CRISPR ?\nY a-t-il des effets à long terme de CRISPR ?",
"url": "https://questionsmedicales.fr/mesh/D064113?mesh_terms=Cryosurgery&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Systèmes CRISPR-Cas",
"description": "Quels sont les facteurs de risque pour l'utilisation de CRISPR ?\nLes personnes âgées sont-elles à risque avec CRISPR ?\nLes maladies auto-immunes augmentent-elles les risques de CRISPR ?\nComment les antécédents familiaux influencent-ils l'utilisation de CRISPR ?\nLes facteurs environnementaux affectent-ils CRISPR ?",
"url": "https://questionsmedicales.fr/mesh/D064113?mesh_terms=Cryosurgery&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un système CRISPR-Cas ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par séquençage génétique et analyse bioinformatique."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter CRISPR ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests PCR et des méthodes de séquençage ciblé sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Peut-on détecter CRISPR dans des échantillons cliniques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des échantillons de sang ou de tissus peuvent être analysés pour CRISPR."
}
},
{
"@type": "Question",
"name": "Quels marqueurs génétiques sont associés à CRISPR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les gènes Cas et les séquences répétées sont des marqueurs clés."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité de CRISPR ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par des tests de modification génétique et d'expression."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent résulter d'une modification CRISPR ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes dépendent de la cible génétique, pouvant inclure des anomalies cellulaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires connus de CRISPR ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires peuvent inclure des réponses immunitaires ou des mutations off-target."
}
},
{
"@type": "Question",
"name": "CRISPR peut-il causer des maladies ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des modifications non ciblées peuvent potentiellement induire des maladies génétiques."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une réponse immunitaire à CRISPR ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes incluent inflammation, douleur ou réactions allergiques au site d'injection."
}
},
{
"@type": "Question",
"name": "Comment surveiller les effets de CRISPR ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance se fait par des examens cliniques réguliers et des tests génétiques."
}
},
{
"@type": "Question",
"name": "CRISPR peut-il prévenir des maladies génétiques ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "CRISPR a le potentiel de prévenir des maladies en corrigeant des mutations héréditaires."
}
},
{
"@type": "Question",
"name": "Comment CRISPR peut-il être utilisé en prévention ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut être utilisé pour modifier des embryons afin d'éliminer des gènes pathogènes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques dans l'utilisation préventive de CRISPR ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des risques incluent des modifications non intentionnelles et des effets à long terme inconnus."
}
},
{
"@type": "Question",
"name": "Quels protocoles de sécurité existent pour CRISPR ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des protocoles incluent des tests rigoureux et des évaluations éthiques avant l'application."
}
},
{
"@type": "Question",
"name": "CRISPR peut-il être utilisé pour prévenir des infections ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches explorent l'utilisation de CRISPR pour cibler des virus et bactéries pathogènes."
}
},
{
"@type": "Question",
"name": "CRISPR est-il utilisé pour traiter des maladies ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CRISPR est exploré pour traiter des maladies génétiques et certains cancers."
}
},
{
"@type": "Question",
"name": "Quels types de maladies peuvent être ciblés par CRISPR ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "CRISPR cible des maladies comme la drépanocytose, la fibrose kystique et certains cancers."
}
},
{
"@type": "Question",
"name": "Comment CRISPR est-il administré en traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "CRISPR est généralement administré par injection dans les cellules ou tissus ciblés."
}
},
{
"@type": "Question",
"name": "Quels sont les résultats des essais cliniques avec CRISPR ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les essais montrent des résultats prometteurs, mais nécessitent encore des études approfondies."
}
},
{
"@type": "Question",
"name": "CRISPR peut-il être utilisé en thérapie génique ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CRISPR est une approche innovante en thérapie génique pour corriger des mutations."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec CRISPR ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des réponses immunitaires, des mutations off-target et des infections."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à CRISPR ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi médical étroit et des traitements symptomatiques appropriés."
}
},
{
"@type": "Question",
"name": "CRISPR peut-il entraîner des cancers ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des modifications non ciblées par CRISPR pourraient théoriquement induire des cancers."
}
},
{
"@type": "Question",
"name": "Quels tests sont nécessaires après un traitement CRISPR ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des examens de santé réguliers sont recommandés après traitement."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets à long terme de CRISPR ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets à long terme sont encore mal compris et nécessitent des études approfondies."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour l'utilisation de CRISPR ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents médicaux, des mutations génétiques et des conditions immunitaires."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles à risque avec CRISPR ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées peuvent avoir un risque accru en raison de la fragilité cellulaire."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes augmentent-elles les risques de CRISPR ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies auto-immunes peuvent augmenter le risque de réactions indésirables."
}
},
{
"@type": "Question",
"name": "Comment les antécédents familiaux influencent-ils l'utilisation de CRISPR ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux de maladies génétiques peuvent influencer les décisions thérapeutiques."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux affectent-ils CRISPR ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs environnementaux peuvent influencer l'efficacité et la sécurité de CRISPR."
}
}
]
}
]
}
Pancreatic cancer (PC) continues to rank as one of the deadliest forms of cancer, with the majority of patients being diagnosed with unresectable disease. The implementation of cryoablation-based comp...
A computerized search was conducted in the Medline, Embase, Cochrane Library databases, and Clinicaltrials to retrieve studies published from August 1987 to June 2023. The perioperative outcomes and l...
9 studies including 368 patients were identified. The pooled overall incidence rate was 4% (95%CI: 0-14%; I²=54.06%) for acute pancreatitis, 0% (95%CI: 0-0%; I²=0.0%) for delayed gastric emptying, 0% ...
With the advancements in cryoablation and anti-tumor therapy, cryoablation emerges as a promising treatment modality for patients with unresectable pancreatic cancer. According to existing literature,...
The challenge in the surgical treatment of giant cell tumours of bone is the relatively high recurrence rate after curettage alone. The use of a local adjuvant following curettage, on the other hand, ...
The efficacy of cryosurgery is believed to depend on the thaw time. The presence of adrenaline in local anesthetics affects blood perfusion, and may thus also affect the thaw time. The aim of the pres...
Twelve patients with actinic keratosis in the periorbital region underwent cryosurgery. The temperature was continuously mapped using a high-precision IR camera and was also visually assessed by the s...
The temperature change during thawing showed a triphasic pattern. The thaw time was significantly longer when using an anesthetic with adrenaline. This was observed with both IR thermography and by vi...
The findings indicate that a longer freezing time may be needed when using a local anesthetic without adrenaline to achieve the same cryo-effect as when using a local anesthetic with adrenaline. A lar...
Cryoballoon ablation for pulmonary vein isolation is a time-efficient procedure that can alleviate stress on electrophysiology lab resources. This analysis modeled the impact of cryoballoon ablation o...
Data from centers in Argentina, Mexico, Colombia, and Chile of the were used as inputs for an electrophysiology lab efficiency simulation model. The model used the assumption that either two (today's ...
Data from a total of 232 procedures from six Latin American centers were included in the analysis. The average electrophysiology lab occupancy time for all procedures in Latin America was 132 ± 62 min...
Using real-world, Latin American-specific data, we found that with operational changes, three ablation procedures could feasibly be performed daily, leaving time for an extra electrophysiology procedu...
Cold knife urethrotome was introduced in 1971 and it had an 80% success rate. New advancements in this field have shed light on the use of various lasers such as carbon dioxide, Nd: YAG, KTP, Argon, H...
The aim of this study was to evaluate and compare the fear of cancer recurrence (FCR) in patients diagnosed with a small renal mass (SRM) and managed with either active surveillance (AS) or minimal in...
A total of 398 patients with SRMs (263 AS and 135 CA patients) were retrospectively identified across three institutions and invited to complete the Fear of Cancer Recurrence-Short Form (FCRI-SF) ques...
No statistically significant differences in FCRI-SF score were observed between the AS (mean = 10.9, standard deviation [SD] = 6.9) and CA (mean = 10.2, SD = 7.2) (p = 0.559) patients, with the mean s...
FCR levels were comparable between AS and CA patients, suggesting that treatment decisions should prioritise clinical factors. Up to 28% of AS and CA patients report clinically significant FCR, highli...
Prolonged acute postsurgical pain (PAPSP) contributes to the development of chronic postsurgical pain, impaired rehabilitation, longer hospital stays, and decreased quality of life. For upper extremit...
Atrioventricular nodal reentrant tachycardia (AVNRT) is the most common supraventricular tachycardia referred for ablation. Periprocedural conduction system damage was a primary concern during AVNRT a...
A literature search was performed to identify studies that compared various techniques, including types of radiofrequency ablation (irrigated and nonirrigated) and different sizes of catheter tip cryo...
A total of 27 studies with 5110 patients were included in the analysis. Overall success rates ranged from 89.78% to 100%. Point estimation showed 4-mm cryoablation exhibited an odds ratio of 0.649 (95...
Our study found no significant difference in the incidence of permanent AV block between the types of catheters. The success rates were consistently high across all groups. These findings emphasize th...
The impact of cryoballoon ablation (CBA) for atrial fibrillation (AF) in patients with enlarged left atrium (E-LA) has not been sufficiently clarified. A total of 306 patients underwent an initial CBA...
Breast cancer is the second most common cancer among women in the United States in which the standard of care treatment is surgery with adjunctive therapy. Cryoablation, which destroys the tumor using...